Myrio Therapeutics awarded CUREator grant for pandemic preparedness research
April 8, 2024
Psaio Therapeutics (subsidery of Myrio Therapeutics) is thrilled to announce that it has been selected as a finalist in the 2024 ANZ Advance Biotech Grant Program by Merck Life Science. This award, presented at the AusBiotech 2024 conference in Melbourne last week, recognises our team’s dedication to developing innovative
cancer therapies. To celebrate this achievement, the Merck Life Science
ANZ team visited our Melbourne research facility today.
The grant will support our ongoing research into antibody therapies targeting Prostate-Specific Antigen (PSA) for the treatment of prostate cancer. By leveraging the power of the ReD platform, we aim to deliver targeted antibody-based therapies that improve patient outcomes
We extend our sincere gratitude to Merck Life Science for their support and to our talented team, especially Lauren Pitt, Head of Preclinical, and Ben Kiefel. CEO. Their unwavering commitment to excellence has been instrumental
in our success.
Attending AusBiotech 2024 has been an incredible opportunity to connect with industry leaders and share our vision for the future of cancer treatment. We are inspired by the collective efforts of the biotech community and look forward to contributing to the next wave of healthcare innovation.
#InnovationInHealthcare #BiotechProgress #Cancer #Drugdiscovery